RFA
PCRX icon

Reilly Financial Advisors’s Pacira BioSciences PCRX Stock Holding History

Reilly Financial Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$0 Buy
+5
New +$276 ﹤0.01% 1181

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Reilly Financial Advisors's PCRX Position: Q4 2021 in Review

Reilly Financial Advisors opened a new position in Pacira BioSciences (PCRX) in Q4 2021: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1181 among its holdings.

276 funds tracked by Wall St. Rank hold PCRX as of Q4 2021.

  • Reilly Financial Advisors held 5 shares of Pacira BioSciences worth $0 as of Q4 2021.
  • Pacira BioSciences was a new Reilly Financial Advisors position in Q4 2021.
  • Pacira BioSciences made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #1181 holding.
  • 276 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.